Journal
DIABETES OBESITY & METABOLISM
Volume 11, Issue 5, Pages 445-454Publisher
WILEY
DOI: 10.1111/j.1463-1326.2008.00986.x
Keywords
adiponectin; cardiovascular disease; metabolic syndrome
Categories
Funding
- Swiss National Science Foundation [320080-105836]
- European Community
Ask authors/readers for more resources
Changes in diagnostic criteria have impacted on the definition of the metabolic syndrome. The central aetiological importance of insulin resistance has lessened, while the role of other cardiovascular risk factors has progressively increased. Inflammatory mediators have also been identified as crucial targets for more selective therapies in metabolic syndrome. Among several pro-inflammatory factors, adiponectin has been shown to be associated with reduced cardiovascular risk in metabolic syndrome patients. Here, we review new therapeutic approaches, which could potentially increase adiponectin levels in metabolic syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available